Royal Bank of Canada Has $10.71 Million Stake in Smith & Nephew SNATS, Inc. $SNN

Royal Bank of Canada raised its stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 6.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 337,118 shares of the medical equipment provider’s stock after acquiring an additional 21,039 shares during the quarter. Royal Bank of Canada owned approximately 0.08% of Smith & Nephew SNATS worth $10,713,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in SNN. Goldman Sachs Group Inc. lifted its stake in Smith & Nephew SNATS by 49.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after purchasing an additional 583,809 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Smith & Nephew SNATS by 139.9% during the third quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock worth $35,828,000 after buying an additional 575,666 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Smith & Nephew SNATS by 365.1% during the second quarter. BNP Paribas Financial Markets now owns 644,525 shares of the medical equipment provider’s stock worth $19,742,000 after buying an additional 505,934 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Smith & Nephew SNATS during the third quarter worth $14,901,000. Finally, River Road Asset Management LLC increased its holdings in shares of Smith & Nephew SNATS by 13.8% during the fourth quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock worth $103,996,000 after buying an additional 384,926 shares in the last quarter. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on SNN shares. Weiss Ratings downgraded Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, June 11th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a report on Monday, May 25th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew SNATS in a research report on Thursday. Barclays lowered Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research note on Wednesday. Finally, Wall Street Zen cut Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday. Two research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Smith & Nephew SNATS presently has a consensus rating of “Hold” and an average price target of $30.93.

Smith & Nephew SNATS Stock Performance

Shares of NYSE:SNN opened at $30.10 on Friday. The company has a current ratio of 2.14, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS, Inc. has a 52 week low of $28.56 and a 52 week high of $38.79. The firm’s fifty day moving average is $30.46 and its 200-day moving average is $32.12.

Smith & Nephew SNATS Announces Dividend

The business also recently announced a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be issued a dividend of $0.312 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a yield of 205.0%.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.